Online inquiry

IVTScrip™ mRNA-Anti-alpha toxin&
lukE, ASN-1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3296MR)

This product GTTS-WQ3296MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets alpha toxin&
lukE gene. The antibody can be applied in Staphylococcal infections research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq WP_000473596.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2828033; 59700577
UniProt ID P09616; A0A0H2WWN3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-alpha toxin&
lukE, ASN-1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3296MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7553MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GC33
GTTS-WQ14190MR IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-910
GTTS-WQ7289MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FPA-008
GTTS-WQ9313MR IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMP-321
GTTS-WQ7450MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GBR500
GTTS-WQ10858MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA M9346A
GTTS-WQ7889MR IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GSK-249320
GTTS-WQ4969MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA c2G4-N
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW